![Clinical Lung Cancer(@ClinicalLung) 's Twitter Profileg](https://pbs.twimg.com/profile_images/1509602012421410816/Kzn2Fz2w_200x200.jpg)
Clinical Lung Cancer
@ClinicalLung
Peer-reviewed journal covering clinical and translational research of lung and other thoracic cancers published by Elsevier. EIC: Antoinette Wozniak MD
ID:1509590371310911492
https://www.sciencedirect.com/journal/clinical-lung-cancer 31-03-2022 17:56:19
236 Tweets
1,0K Followers
245 Following
![Stephen V Liu, MD(@StephenVLiu) 's Twitter Profile Photo Stephen V Liu, MD(@StephenVLiu) 's Twitter Profile Photo](https://pbs.twimg.com/profile_images/1446648362720190464/QJrFLJxM_200x200.jpg)
![Clinical Lung Cancer(@ClinicalLung) 's Twitter Profile Photo Clinical Lung Cancer(@ClinicalLung) 's Twitter Profile Photo](https://pbs.twimg.com/profile_images/1509602012421410816/Kzn2Fz2w_200x200.jpg)
A case report just published Clinical Lung Cancer
A novel PRKAR1A::MET fusion responing to crizotinib in a patient with unresectable lung cancer
Learn more: bit.ly/3esAx2H
![Clinical Lung Cancer (@ClinicalLung) on Twitter photo 2022-10-14 10:00:16 A case report just published @ClinicalLung A novel PRKAR1A::MET fusion responing to crizotinib in a patient with unresectable lung cancer Learn more: bit.ly/3esAx2H A case report just published @ClinicalLung A novel PRKAR1A::MET fusion responing to crizotinib in a patient with unresectable lung cancer Learn more: bit.ly/3esAx2H](https://pbs.twimg.com/media/FfBYXpZXgAA8a1r.jpg)
![Clinical Lung Cancer(@ClinicalLung) 's Twitter Profile Photo Clinical Lung Cancer(@ClinicalLung) 's Twitter Profile Photo](https://pbs.twimg.com/profile_images/1509602012421410816/Kzn2Fz2w_200x200.jpg)
Immune-related myelitis is rare, but it can lead to significant morbidity.
A case report published Clinical Lung Cancer suggests that the combination of upfront IVIg with steroids is a reasonable treatment option for immune-related myelitis.
Learn more: bit.ly/3VokTWm
![Clinical Lung Cancer (@ClinicalLung) on Twitter photo 2022-10-12 16:49:28 Immune-related myelitis is rare, but it can lead to significant morbidity. A case report published @ClinicalLung suggests that the combination of upfront IVIg with steroids is a reasonable treatment option for immune-related myelitis. Learn more: bit.ly/3VokTWm Immune-related myelitis is rare, but it can lead to significant morbidity. A case report published @ClinicalLung suggests that the combination of upfront IVIg with steroids is a reasonable treatment option for immune-related myelitis. Learn more: bit.ly/3VokTWm](https://pbs.twimg.com/media/Fe4iJfUX0AErhgn.jpg)
![Clinical Lung Cancer(@ClinicalLung) 's Twitter Profile Photo Clinical Lung Cancer(@ClinicalLung) 's Twitter Profile Photo](https://pbs.twimg.com/profile_images/1509602012421410816/Kzn2Fz2w_200x200.jpg)
A new case report published Clinical Lung Cancer
U.S. FDA analysis of newly identified adverse events with #Lurbinectedin : Extravasation, Rhabdomyolysis, and Tumor Lysis Syndrome
Learn more: bit.ly/3SPLKso
![Clinical Lung Cancer (@ClinicalLung) on Twitter photo 2022-10-02 01:52:50 A new case report published @ClinicalLung U.S. FDA analysis of newly identified adverse events with #Lurbinectedin: Extravasation, Rhabdomyolysis, and Tumor Lysis Syndrome Learn more: bit.ly/3SPLKso A new case report published @ClinicalLung U.S. FDA analysis of newly identified adverse events with #Lurbinectedin: Extravasation, Rhabdomyolysis, and Tumor Lysis Syndrome Learn more: bit.ly/3SPLKso](https://pbs.twimg.com/media/FeB0ZW5XEAIc29p.jpg)
![Clinical Lung Cancer(@ClinicalLung) 's Twitter Profile Photo Clinical Lung Cancer(@ClinicalLung) 's Twitter Profile Photo](https://pbs.twimg.com/profile_images/1509602012421410816/Kzn2Fz2w_200x200.jpg)
MET is an actionable biomarker in NSCLC
A new review article on MET alterations in NSCLC published Clinical Lung Cancer
Asian Thoracic Oncology Research Group Expert Consensus Statement on MET Alterations in NSCLC: Diagnostic and Therapeutic Considerations
bit.ly/3LZINUb
![Clinical Lung Cancer (@ClinicalLung) on Twitter photo 2022-10-02 01:40:00 MET is an actionable biomarker in NSCLC A new review article on MET alterations in NSCLC published @ClinicalLung Asian Thoracic Oncology Research Group Expert Consensus Statement on MET Alterations in NSCLC: Diagnostic and Therapeutic Considerations bit.ly/3LZINUb MET is an actionable biomarker in NSCLC A new review article on MET alterations in NSCLC published @ClinicalLung Asian Thoracic Oncology Research Group Expert Consensus Statement on MET Alterations in NSCLC: Diagnostic and Therapeutic Considerations bit.ly/3LZINUb](https://pbs.twimg.com/media/FeBuhdZXwAAvht8.jpg)
![Stephen V Liu, MD(@StephenVLiu) 's Twitter Profile Photo Stephen V Liu, MD(@StephenVLiu) 's Twitter Profile Photo](https://pbs.twimg.com/profile_images/1446648362720190464/QJrFLJxM_200x200.jpg)
![Clinical Lung Cancer(@ClinicalLung) 's Twitter Profile Photo Clinical Lung Cancer(@ClinicalLung) 's Twitter Profile Photo](https://pbs.twimg.com/profile_images/1509602012421410816/Kzn2Fz2w_200x200.jpg)
![Clinical Lung Cancer(@ClinicalLung) 's Twitter Profile Photo Clinical Lung Cancer(@ClinicalLung) 's Twitter Profile Photo](https://pbs.twimg.com/profile_images/1509602012421410816/Kzn2Fz2w_200x200.jpg)
![Clinical Lung Cancer(@ClinicalLung) 's Twitter Profile Photo Clinical Lung Cancer(@ClinicalLung) 's Twitter Profile Photo](https://pbs.twimg.com/profile_images/1509602012421410816/Kzn2Fz2w_200x200.jpg)
Just out Clinical Lung Cancer!
First-line #pembrolizumab in metastatic NSCLC with MET exon 14 skipping mutation and PD-L1 ≥50% (GFPC 01-20 study)
The obective response rate was 43% (14% complete response) with duration of response 13.9 months.
Learn more: bit.ly/3BpQMER
![Clinical Lung Cancer (@ClinicalLung) on Twitter photo 2022-09-17 08:11:36 Just out @ClinicalLung! First-line #pembrolizumab in metastatic NSCLC with MET exon 14 skipping mutation and PD-L1 ≥50% (GFPC 01-20 study) The obective response rate was 43% (14% complete response) with duration of response 13.9 months. Learn more: bit.ly/3BpQMER Just out @ClinicalLung! First-line #pembrolizumab in metastatic NSCLC with MET exon 14 skipping mutation and PD-L1 ≥50% (GFPC 01-20 study) The obective response rate was 43% (14% complete response) with duration of response 13.9 months. Learn more: bit.ly/3BpQMER](https://pbs.twimg.com/media/Fc16FlGWAAAGX3c.jpg)
![Clinical Lung Cancer(@ClinicalLung) 's Twitter Profile Photo Clinical Lung Cancer(@ClinicalLung) 's Twitter Profile Photo](https://pbs.twimg.com/profile_images/1509602012421410816/Kzn2Fz2w_200x200.jpg)
![Clinical Lung Cancer(@ClinicalLung) 's Twitter Profile Photo Clinical Lung Cancer(@ClinicalLung) 's Twitter Profile Photo](https://pbs.twimg.com/profile_images/1509602012421410816/Kzn2Fz2w_200x200.jpg)
Comprehensive review of immunotherapy in advanced NSCLC without driver mutations: availble therapeutic alternatives after progression and future treatment options
Authored by Dr. Jose Luis Leal and Dr. A/Prof Tom John.
Learn more: bit.ly/3BgDYAK
![Clinical Lung Cancer (@ClinicalLung) on Twitter photo 2022-09-16 12:58:15 Comprehensive review of immunotherapy in advanced NSCLC without driver mutations: availble therapeutic alternatives after progression and future treatment options Authored by Dr. Jose Luis Leal and Dr. @TommyJohn00. Learn more: bit.ly/3BgDYAK Comprehensive review of immunotherapy in advanced NSCLC without driver mutations: availble therapeutic alternatives after progression and future treatment options Authored by Dr. Jose Luis Leal and Dr. @TommyJohn00. Learn more: bit.ly/3BgDYAK](https://pbs.twimg.com/media/FcxzS1QWAAEqCKP.jpg)
![Clinical Lung Cancer(@ClinicalLung) 's Twitter Profile Photo Clinical Lung Cancer(@ClinicalLung) 's Twitter Profile Photo](https://pbs.twimg.com/profile_images/1509602012421410816/Kzn2Fz2w_200x200.jpg)
![Clinical Lung Cancer(@ClinicalLung) 's Twitter Profile Photo Clinical Lung Cancer(@ClinicalLung) 's Twitter Profile Photo](https://pbs.twimg.com/profile_images/1509602012421410816/Kzn2Fz2w_200x200.jpg)
![Clinical Lung Cancer(@ClinicalLung) 's Twitter Profile Photo Clinical Lung Cancer(@ClinicalLung) 's Twitter Profile Photo](https://pbs.twimg.com/profile_images/1509602012421410816/Kzn2Fz2w_200x200.jpg)
![Clinical Lung Cancer(@ClinicalLung) 's Twitter Profile Photo Clinical Lung Cancer(@ClinicalLung) 's Twitter Profile Photo](https://pbs.twimg.com/profile_images/1509602012421410816/Kzn2Fz2w_200x200.jpg)
Intraocular metastasis from lung cancer can lead to significant morbidity.
A systematic review and pooled analysis published Clinical Lung Cancer indicates that systemic therapy can be effective, especially when targeted therapy is feasible.
Learn more: bit.ly/3pBA7J0
![Clinical Lung Cancer (@ClinicalLung) on Twitter photo 2022-08-22 01:51:48 Intraocular metastasis from lung cancer can lead to significant morbidity. A systematic review and pooled analysis published @ClinicalLung indicates that systemic therapy can be effective, especially when targeted therapy is feasible. Learn more: bit.ly/3pBA7J0 Intraocular metastasis from lung cancer can lead to significant morbidity. A systematic review and pooled analysis published @ClinicalLung indicates that systemic therapy can be effective, especially when targeted therapy is feasible. Learn more: bit.ly/3pBA7J0](https://pbs.twimg.com/media/FaupLA9X0AI6vHB.jpg)
![Clinical Lung Cancer(@ClinicalLung) 's Twitter Profile Photo Clinical Lung Cancer(@ClinicalLung) 's Twitter Profile Photo](https://pbs.twimg.com/profile_images/1509602012421410816/Kzn2Fz2w_200x200.jpg)
![Clinical Lung Cancer(@ClinicalLung) 's Twitter Profile Photo Clinical Lung Cancer(@ClinicalLung) 's Twitter Profile Photo](https://pbs.twimg.com/profile_images/1509602012421410816/Kzn2Fz2w_200x200.jpg)
Retrospective analysis of patients with advanced NSCLC treated across 12 Australian sites explored efficay and tolerability of the #IMpower150 regimen (atezolizumab, bevacizumab, platinum doublet chemotherapy) in oncogene driven tumors and CNS metastases.
bit.ly/3pw7Ljr
![Clinical Lung Cancer (@ClinicalLung) on Twitter photo 2022-08-20 00:23:54 Retrospective analysis of patients with advanced NSCLC treated across 12 Australian sites explored efficay and tolerability of the #IMpower150 regimen (atezolizumab, bevacizumab, platinum doublet chemotherapy) in oncogene driven tumors and CNS metastases. bit.ly/3pw7Ljr Retrospective analysis of patients with advanced NSCLC treated across 12 Australian sites explored efficay and tolerability of the #IMpower150 regimen (atezolizumab, bevacizumab, platinum doublet chemotherapy) in oncogene driven tumors and CNS metastases. bit.ly/3pw7Ljr](https://pbs.twimg.com/media/Faj9SAFXoAI0KTY.png)
![Clinical Lung Cancer(@ClinicalLung) 's Twitter Profile Photo Clinical Lung Cancer(@ClinicalLung) 's Twitter Profile Photo](https://pbs.twimg.com/profile_images/1509602012421410816/Kzn2Fz2w_200x200.jpg)